BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-758@pharmaconomics
DTSTAMP:20260707T030330Z
DTSTART;VALUE=DATE:20260430
DTEND;VALUE=DATE:20260501
SUMMARY:LLY Phase 3 — retatrutide
DESCRIPTION:Phase 3 trial results for retatrutide in type 2 diabetes are due Apr 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000043/q126lillysalesandearningsp.htm\n\nTrack it: https://pharmaconomics.com/e/758
URL:https://pharmaconomics.com/e/758
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:LLY catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR